Drugs / AT-752
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05366439 | Apr 2022 → Mar 2023 | dengue disease | Atea Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04722627 | Mar → Nov 2021 | dengue disease | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05466240 Comparator | Apr 2022 → Jan 2023 | dengue disease | Atea Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2023-04-12 | Atea Pharmaceuticals, Inc. | Results Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases ateapharma.com ↗
Results indicated that AT-752 did not affect cardiac repolarization in healthy participants and that AT-752 was well tolerated after single and multiple oral doses. |
| 2023-03-14 | Atea Pharmaceuticals, Inc. | Results New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research ateapharma.com ↗
RNA synthesis inhibition occurred for all 4 DENV serotypes. |
| 2022-11-03 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting ateapharma.com ↗
These data demonstrate that AT-752 was well tolerated up to the highest dose tested and rapidly achieved plasma levels above the in vitro EC 90 . |
| 2022-09-26 | Atea Pharmaceuticals, Inc. | Regulatory Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue ateapharma.com ↗
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AT-752, a novel, orally administered, direct-acting antiviral for the treatment of dengue virus infection. |
| 2021-08-24 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses ateapharma.com ↗
The published data demonstrate that AT-752 has potent in vitro activity against multiple dengue virus serotypes and other flaviviruses tested, and reduces viremia and improves survival in an animal model of dengue disease. |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT-752 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05366439 ↗ |
| Action | Inhibit | “inhibitor of the dengue virus (DENV) polymerase” PMID 38526047 ↗ Mar 2024 |
| Modality | Other / unclassified | “AT-752 is a novel guanosine nucleotide prodrug” PMID 38526047 ↗ Mar 2024 |
| Route | Oral | “AT-752 administered orally” NCT04722627 ↗ |